Victoza vs Ozempic: Novo Nordisk's Two GLP-1 Options

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

From the PlexusDx Education Hub: evidence-led comparisons of GLP-1 therapies and the genetic factors that sit beneath every prescribing decision. Browse all Peptides & GLP-1 education

This is an independent editorial comparison. PlexusDx has no commercial relationship with Novo Nordisk.

Victoza and Ozempic are both Novo Nordisk GLP-1 agonists, but they arrived years apart and behave differently at the dosing counter — daily versus weekly, first-generation versus a later refinement. This comparison walks through molecular design, approved indications, the trial evidence, safety, and price as of April 2026, then closes on the genetic variables that apply to both.

Novo Nordisk's older and newer GLP-1, compared

Victoza is a human glucagon-like peptide-1 (GLP-1) receptor agonist with 97% sequence homology to native GLP-1, from Novo Nordisk. Ozempic is a selective GLP-1 receptor agonist, also from Novo Nordisk. Both bind the GLP-1 receptor across the pancreas, hypothalamus, and gut — slowing gastric emptying, blunting post-meal glucose, and raising satiety signaling. Tirzepatide-based compounds add GIP-receptor agonism, one of the defining molecular splits in this category.

Approved uses and why they diverge

Victoza is FDA-approved for type 2 diabetes (2010) and to reduce major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Ozempic is FDA-approved for type 2 diabetes (2017), with the same active ingredient widely studied for weight management. These approval scopes govern how each can be prescribed and whether insurance treats the cost as covered.

Reading the LEAD, LEADER and SUSTAIN evidence

Victoza was evaluated in the LEAD and LEADER programs, while Ozempic was evaluated in the SUSTAIN program for cardiovascular and glycemic outcomes. Some comparisons are indirect, and SURPASS evaluated tirzepatide head-to-head against semaglutide 1 mg in type 2 diabetes. Because trial populations and primary endpoints differ, the cleanest interpretation is per-trial rather than a blanket winner.

Safety profile across both

Both carry the GLP-1 class boxed warning tied to thyroid C-cell tumor risk observed in rodent studies. The most common side effects for each are gastrointestinal — nausea, vomiting, diarrhea, constipation — usually most pronounced during dose escalation. Serious events reported across the class include pancreatitis, gallbladder events, and acute kidney injury in the setting of dehydration.

List prices and coverage realities

Victoza's U.S. list price is approximately $815 per month as of April 2026 (Novo Nordisk published pricing). Ozempic's U.S. list price is approximately $968–$1,029 per month as of April 2026 (Novo Nordisk published pricing). Out-of-pocket cost depends heavily on insurance coverage, manufacturer savings cards, the specific FDA indication on the prescription, and whether a compounded alternative is available through a licensed compounding pathway.

The genes underneath both prescriptions

Whichever molecule a clinician chooses, the upstream genetics are shared. Variants in FTO (the fat-mass and obesity-associated gene; influences appetite regulation and adiposity set-point), GLP1R (which encodes the GLP-1 receptor both compounds engage), and MC4R (a melanocortin receptor central to energy balance) — among others — shape baseline satiety and energy expenditure. These are pathway-level markers; they do not predict response to Victoza, Ozempic, or any single compound.

PlexusDx does not sell, distribute, or prescribe liraglutide; it offers semaglutide through its Weight Management Protocols. Whichever GLP-1 pathway compound you and your provider land on, the underlying architecture is the same. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including FTO, GLP1R, and MC4R variants that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. That is the test before you invest approach.

Related reading on PlexusDx: Natural Ozempic, Ozempic What is It, Injection Sites for Ozempic, Ozempic Price with Insurance.

Disclaimer: This is educational content. PlexusDx offers semaglutide through its Weight Management Protocols and does not sell, prescribe, or recommend liraglutide. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Begin with your own biology. Take the Precision Peptide Genetic Test, or explore the Weight Management Protocols.

Frequently Asked Questions

What is the core mechanical difference between Victoza and Ozempic?

Both are GLP-1-selective receptor agonists from Novo Nordisk, so neither engages the GIP receptor. They differ in molecule (liraglutide versus semaglutide), half-life, and dosing frequency — Victoza is daily, Ozempic is weekly — which changes the day-to-day routine more than the underlying receptor target.

Is one clearly more effective than the other?

Trial populations, doses, and endpoints differ, so the honest answer is per-trial. Indirect comparisons and head-to-head SURPASS data inform clinical discussion, but individual response varies. The upstream genetic pathway applies to both compounds and is independent of which molecule a provider ultimately prescribes.

Can the genetic test tell me which to choose?

No. The Precision Peptide Genetic Test does not predict response to Victoza, Ozempic, or any specific medication. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and related genes that shape baseline GLP-1 biology — context that applies regardless of which compound a clinician recommends.

Do the two differ on side effects?

The side-effect profile is similar across the GLP-1 class, with gastrointestinal symptoms most common. Both carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies. Discuss your full medical history with a provider before starting either medication.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.